Welcome to our dedicated page for Perspective Therapeutics news (Ticker: CATX), a resource for investors and traders seeking the latest updates and insights on Perspective Therapeutics stock.
Perspective Therapeutics develops radiopharmaceutical candidates for cancer using proprietary Lead-212 (212Pb) technology and specialized targeting moieties. Its updates center on a theranostic approach that pairs targeted alpha therapy with complementary imaging diagnostics.
Recurring CATX news covers clinical and conference updates for VMT-α-NET in SSTR2-expressing neuroendocrine tumors, VMT01 for melanoma, and PSV359 for solid tumors, along with business results, financing activity, manufacturing infrastructure, 212Pb generator-enabled finishing facilities, and corporate presentations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.